Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 2 publications
A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.
Journal: Leukemia & lymphoma
Published: April 01, 2014
Sequential single-agent obatoclax mesylate (GX15-070MS) followed by combination with rituximab in patients with previously untreated follicular lymphoma.
Journal: Leukemia & lymphoma
Published: March 12, 2014
Showing 1-2 of 2
Last Updated: 09/26/2026